[4-(Phenoxy)pyridin-3-yl]methylamines: A new class of selective noradrenaline reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 1795-1798

  Fish, Paul V ^a   Ryckmans, Thomas ^a   Stobie, Alan ^a   Wakenhut, Florian ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Noradrenaline reuptake inhibitor; NRI; Pyridinyl phenyl ether

Indexed keywords

[4 (PHENOXY)PYRIDIN 3 YL]METHYLAMINE DERIVATIVE; ATOMOXETINE; DOPAMINE; NORADRENALIN UPTAKE INHIBITOR; PF 3665343; REBOXETINE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; IN VIVO STUDY; INHIBITION KINETICS; LIPOPHILICITY; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; RAT; STRUCTURE ACTIVITY RELATION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; ETHER-A-GO-GO POTASSIUM CHANNELS; EXTRACELLULAR FLUID; HEPATOCYTES; HUMANS; METHYLAMINES; MICRODIALYSIS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NOREPINEPHRINE; PREFRONTAL CORTEX; PYRIDINES; RATS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 40749102445     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.02.036     Document Type: Article

References (24)

1. Babu R.P.K., and Maiti S.N. Heterocycles 69 (2006) 539
2. For a recent review of new chemical entities, see. Walter M.W. Drug Dev. Res. 65 (2005) 97
3. Ledbetter M. Neuropsychol. Dis. Treat. 2 (2006) 455
4. Hajos M., Fleishaker J.C., Filipiak-Reisner J.K., Brown M.T., and Wong E.H.F. CNS Drug Rev. 10 (2004) 23
5. Fray M.J., Bish G., Brown A.D., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4345
6. Fray M.J., Bish G., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4349
7. Fish P.V., Fray M.J., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 17 (2007) 2022
8. Whitlock G.A., Fish P.V., and Blagg J. Bioorg. Med. Chem. Lett. 18 (2008) 596
9. Fish, P. V.; Mackenny, M. C.; Stobie, A.; Wakenhut, F.; Whitlock, G. A. WO Patent 105100, 2005.
10. Adam, M. D.; Andrews, M. D.; Gymer, G. E.; Hepworth, D.; Howard, H. R., Jr.; Middleton, D. S.; Stobie, A. WO Patent 083643, 2002.
11. Whitlock, G. A.; Fish, P. V.; Fray, M. J.; Stobie, A.; Wakenhut, F. Bioorg. Med. Chem. Lett., submitted for publication.
12. Li Y., Wang D., Yu X., and Xu S. Shenyang Yaoke Daxue Xuebao 22 (2005) 17 CAN 146:121716
13. 3 = OPh which was prepared as shown.{A figure is presented}
14. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. J. Pharmacol. Exp. Ther. 303 (2002) 1029
15. The Me group adjacent to the pyridine N atom was retained in all targets in order to reduce the liability of CYP450 inhibition. See. Blagg J. Annu. Rep. Med. Chem. 41 (2006) 353
16. 3 (π): OMe (-0.02); OEt (0.38); Me (0.56); SMe (0.61); Cl (0.71); Et (1.02); i-Pr (1.53); n-Pr (1.55); OPh (2.08).
17. van de. Waterbeemd H., Smith D.A., Beaumont K., and Walker D.K. J. Med. Chem. 44 (2001) 1313
18. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Disc. 6 (2007) 881
19. Hughes, J. D.; Blagg, J.; Bailey, S.; De Crescenzo, G. A.; Dalvie, D.; Devraj, R. V.; Doubovetzky, M.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Grant, D.; Greene, N.; Huang, E.; Kreiger-Burke, T.; Lee, L.; Loesel, J.; Nahas, K.; Price, D. A.; Wager, T.; Whiteley, L.; Zhang, Y., Nat. Biotechnol., in press.
20. 1/2 > 120 min.
21. Deecher D.C., Beyer C.E., Johnston G., Bray J., Shah S., Abou-Gharbia M., and Andree T.H. J. Pharmacol. Exp. Ther. 318 (2006) 657
22. 50 = 2.5 nM (n = 7).
23. 3H salt: mp 155 °C.
24. There is a significant discrepancy between calculated c log P (4.4) and measured log P (3.2) values for 31. It is our hypothesis that 31 undergoes hydrophobic collapse to adopt a folded structure and so reduce the exposure of lipophilic faces.